What This Report
Will Provide?
This study involved four major
activities in estimating the current size of the newborn screening market.
Exhaustive secondary research was carried out to collect information on the
market, its peer markets, and its parent market.
The next step was to validate these findings, assumptions, and sizing with
industry experts across the value chain through primary research. Both top-down
and bottom-up approaches were employed to estimate the complete market size.
After that, market breakdown and data triangulation procedures were used to
estimate the size of segments and subsegments.
Expected Revenue Growth:
[177 Pages Report] The newborn screening market size is projected to reach USD 1.3 billion by
2026 from USD 0.9 billion in 2021, at a CAGR of 8.3%
Major Growth Boosters:
Growth
in this market is majorly driven by the increasing prevalence of newborn
disorders, favourable reimbursement polcies. However, the availability of
refurbished products are expected to restrain the growth of this market to certain
extent during the forecast period.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=141676244
Recent Developments:
In September 2020, PerkinElmer (US) recevied CE-IVD approval for
EONIS screening assay used to screen SMA (spinal muscular atrophy), SCID
(severe combined immunodeficiency), and XLA (X-linked agammaglobulinemia) in newborns
In December 2019, PerkinElmer (US) received US FDA approval for GSP Neonatal
Creatine Kinase –MM (CK-MM) kit for screening newborns affected by Duchenne
muscular dystrophy (DMD)
In October 2019, Demant A/S (Denmark) has lancuehd its easyScreen BERAphone, a
hearing screening device, at the 64th International Congress of Hearing Aid
Acousticians in Nuremberg, Germany
In January 2018, Demant A/S (Denmark) has launched GSI Novus, a handheld
newborn hearing screener
Regional Growth Analysis:
The newborn screening market,
by region, has been segmented into North America, Europe, the Asia Pacific, and
the Rest of the world (RoW). North America is the largest market for newborn
screening, followed by Europe. Growth in the North American market can be
attributed to the availability of newborn screening programs, favorable
reimbursement policies, and a strong market player presence.
The Asia Pacific is expected to register the highest CAGR during the forecast
period. Growth in this region is driven by the large newborn pool, increasing
screening rate, and rising awareness regarding early diagnosis. India, China,
and Brazil provide significant opportunities to players in this market due to
their high birth rates and increasing disposable income.
Key Questions Addressed in The Report:
1. Who are the top 10 players operating in the newborn screening market?
2. What are the drivers, restraints, opportunities, and challenges in the newborn
screening Industry?
3. What are the opportunities for stakeholders and provide details of the
competitive landscape for key players?
4. What will be growth of newborn screening in North America, Europe, Asia
Pacific, Latin America, and the Middle East and Africa?
Request Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=141676244
Key Players:
Prominent
players in the newborn screening market are PerkinElmer (US), Natus Medical
(US), Bio-Rad Laboratories (US), Danaher Corporation (US), and Medtronic
(Ireland). Others include Chromsystems Instruments & Chemicals GmbH
(Germany), Trivitron Healthcare (India), Baebies (US), Parseq Lab (Russia),
Recipe Chemicals+Instruments (Germany), and Demant A/S (Denmark).
